Medicare Drug Price Negotiations Expected to Generate $1.8 Billion in Savings by 2026

By Staff Writer

August 29, 2023

Starting in 2026, Medicare will have the ability to negotiate drug prices, potentially generating significant savings. According to a recent study, the minimum discount stipulated by the Inflation Reduction Act exceeds 2020 rebates for 4 of the 10 drugs expected to be negotiated in 2026.

These include the drug etanercept, which will be subject to a minimum discount of 60%, compared to an estimated rebate of 39.1%, and the cancer drugs ibrutinib, palbociclib, and enzalutamide, all of which will be subject to a minimum discount of 25%, compared with estimated rebates of 9%, 5.7% and 15.0%, respectively.

Based on 2020 gross spending, the minimum required discount on these four drugs would generate savings of $1.8 billion. However, to achieve the savings projected by the Congressional Budget Office ($3.7 billion), negotiated prices will have to fall below the maximum negotiated price.

The negotiated price will be capped at the greater of the net price after rebates or a maximum percentage of the list price based on the drug’s age. In 2026, current prices paid by Medicare plans will set the cap for the negotiated price for six drugs; minimum discounts based on a drug’s age will apply to the remaining four.

The study also highlights the importance of current rebates for drugs in competitive therapeutic classes in the setting of maximum discounted prices under Medicare price negotiations. The analysis also indicates that the statutory minimum discounts under the Inflation Reduction Act will not be sufficient to achieve the savings estimated by the Congressional Budget Office associated with drug price negotiation. These additional savings below the ceilings for negotiated prices correspond to $1.9 billion or an average 10% discount off the maximum negotiated price for the 10 drugs expected to face negotiation in 2026.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.